|
Scientia
Veritas (SV) is pleased to announce the publication of Update 2 of
SV’s Stroke Management Markets and Strategies market
research report. This update constitutes the second revision
of Scientia Veritas’s (SV’s) Stroke Management Markets and
Strategies report, originally published in April 2003.
Purchasers of the report were automatically sent the first update.
Both updates include news concerning products in development,
product approvals, company news, and mergers and acquisitions.
This revision, Update 2, includes all information previously printed
in Update 1. This update has been sent to all clients who
purchased the original report. Stroke Management Markets and
Strategies is available on our website at www.ScientiaVeritas.com/StrokeManagement.asp.
The report, published in
April 2003, is 345 pages and includes 144 exhibits. It is
available in file download, CD, and hard copy formats.
To
download a complete Table of Contents and List of Exhibits (free),
go to www.ScientiaVeritas.com/TOC-LOEs.asp
or contact us at
Healthcare@ScientiaVeritas.com
In
honor of the publication of Update 2, Stroke
Management Markets and Strategies will
be on sale through the month of February 2005.
Download
Update 2 Here FREE!
The
market for stroke diagnosis, pharmaceuticals, devices, and surgical
intervention is projected to reach nearly $4.7 billion in 2005.
Stroke prevention and treatment pharmaceuticals are projected to
account for the largest share of the market, at 50.3%; diagnosis
will be second, at 27.0%; surgical intervention, 15.5%; and devices,
7.2%. (For complete figures and market share data for each
category, see Stroke Management Markets and Strategies.)
Among
pharmaceutical products specifically indicated for stroke, both Cozaar
and Exanta continue to provide news. In 2003, Cozaar
became the first antihypertensive approved for use in reducing the
risk of stroke among patients with hypertension and left-ventricular
hypertrophy. The Exanta saga continues, as the first
oral anticoagulant in 50 years awaits U.S. marketing approval.
The
most important recent approval on the device front was that of
Guidant’s Acculink and RX Acculink Carotid Stent System.
The first-of-its-kind approval marked the introduction of a
minimally invasive alternative to carotid endarterectomy for
patients at high surgical risk.
Schering
AG is paying increased attention to its diagnostics and
radiopharmaceuticals sector, which posted net sales of $1.48 billion
in 2003. The company’s most important contrast media are Iopamiron
and Ultravist. Both are nonionic products used in a
wide range of indications in computer tomography, including
diagnosis of strokes, kidney diseases, and cardiac diseases.
Sales of Schering’s Magnevist magnetic resonance imaging (MRI)
contrast agent totaled $339.5 million in 2003.
Schering’s
MS-325 MRI contrast agent is awaiting U.S. marketing approval.
The product is injected intravenously, then it binds reversibly to
human serum albumin in the plasma, providing prolonged vascular
enhancement and imaging. MS-325 was developed by Epix
Pharmaceuticals Inc.; Schering AG is Epix’s worldwide sales,
marketing, and development partner for MS-325. In October
2004, Schering announced that the FDA had extended the New Drug
Application (NDA) review date until January 2005. No reason
was given for the extension, nor was any additional documentation
requested.
The
biggest competitor news in the industry is the proposed merger
between Johnson & Johnson (J&J) and Guidant. The
agreement, announced December 15, 2004, calls for an exchange of
stock and cash valued at $23.9 billion.
About
Scientia Veritas:
Scientia Veritas (SV) was founded in 1997 and offers both
Healthcare and Toxicology/Risk Assessment products and services. Our Healthcare Division publishes market research reports,
writes journal articles and book chapters, develops continuing
education materials for medical professionals, and performs a
variety of custom work. SV’s
Toxicology/Risk Assessment Division offers products and services
that include human and ecological risk assessment, development of
guidance documents, expert witness testimony, toxic tort support,
statistical analysis, and training and seminars.
SV provides expertise to a variety of public and private
clients, including a wide range of healthcare publishing companies,
physicians, pharmaceutical suppliers, medical device suppliers, the
Department of Justice, Department of the Navy, and Environmental
Protection Agency.
Reports coming soon include Anti-Infectives Markets
and Strategies; Home Care Services Markets and Strategies; Long-Term
Care Markets and Strategies; Men's Cancer Markets and Strategies:
BPH, Prostate Cancer, and Testicular Cancer; Pain Management Markets
and Strategies; Women's Cancer Markets and Strategies: Breast,
Cervical, Endometrial, and Ovarian Cancers; and Wound Care
Markets and Strategies.
Contact:
Patricia DeGrandchamp, Healthcare@scientiaveritas.com;
Tel: (303) 674-3732;
Fax: (303) 674-8755
|
Scientia
Veritas, L.L.P.
